The value of [11C]-acetate PET and [18F]-FDG PET in hepatocellular carcinoma before and after treatment with transarterial chemoembolization and bevacizumab

@inproceedings{Li2017TheVO,
  title={The value of [11C]-acetate PET and [18F]-FDG PET in hepatocellular carcinoma before and after treatment with transarterial chemoembolization and bevacizumab},
  author={Shuren Li and Markus Peck-Radosavljevic and Philipp Ubl and Wolfgang Wadsak and Markus Mitterhauser and Eva Rainer and Matthias Pinter and Hao Wang and Christian Nanoff and Klaus Kaczirek and Alexander R Haug and Marcus Hacker},
  booktitle={European Journal of Nuclear Medicine and Molecular Imaging},
  year={2017}
}
This prospective study was to investigate the value of [11C]-acetate PET and [18F]-FDG PET in the evaluation of hepatocellular carcinoma (HCC) before and after treatment with transarterial chemoembolization (TACE) and vascular endothelial growth factor (VEGF) antibody (bevacizumab). Twenty-two patients (three women, 19 men; 62 ± 8 years) with HCC verified… CONTINUE READING